These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 9516894

  • 1. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist.
    Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E, Guerreiro D, Hendeles L.
    Thorax; 1997 Dec; 52(12):1030-5. PubMed ID: 9516894
    [Abstract] [Full Text] [Related]

  • 2. [Single dose of montelukast as an effective prevention of post exercise bronchospasm in children with bronchial asthma].
    Gaszczyk G, Latoś T, Słowikowski A, Janiak B.
    Med Wieku Rozwoj; 2004 Dec; 8(3 Pt 2):847-56. PubMed ID: 15858257
    [Abstract] [Full Text] [Related]

  • 3. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
    Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF.
    N Engl J Med; 1998 Jul 16; 339(3):147-52. PubMed ID: 9664090
    [Abstract] [Full Text] [Related]

  • 4. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma.
    Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, Cmiel A, Szczeklik A.
    Clin Exp Allergy; 2002 Sep 16; 32(9):1360-5. PubMed ID: 12220476
    [Abstract] [Full Text] [Related]

  • 5. Role of cysteinyl leukotrienes in adenosine 5'-monophosphate induced bronchoconstriction in asthma.
    Rorke S, Jennison S, Jeffs JA, Sampson AP, Arshad H, Holgate ST.
    Thorax; 2002 Apr 16; 57(4):323-7. PubMed ID: 11923550
    [Abstract] [Full Text] [Related]

  • 6. [The effect of montelukast, a leukotriene antagonist, on improvement of exercise-induced bronchoconstriction].
    Sun TY, Guo YF, Xu XM, Zhang HS, Hou J, Ke HX, Li YM, Fang BM, Ming SH.
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb 16; 28(2):83-7. PubMed ID: 15854387
    [Abstract] [Full Text] [Related]

  • 7. Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor.
    Lazarinis N, Bood J, Gomez C, Kolmert J, Lantz AS, Gyllfors P, Davis A, Wheelock CE, Dahlén SE, Dahlén B.
    J Allergy Clin Immunol; 2018 Oct 16; 142(4):1080-1089. PubMed ID: 29518425
    [Abstract] [Full Text] [Related]

  • 8. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma.
    Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B.
    J Pediatr; 1998 Sep 16; 133(3):424-8. PubMed ID: 9738728
    [Abstract] [Full Text] [Related]

  • 9. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval.
    Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF.
    Clin Pharmacol Ther; 1997 Nov 16; 62(5):556-61. PubMed ID: 9390112
    [Abstract] [Full Text] [Related]

  • 10. Effects of montelukast on airway narrowing from eucapnic voluntary hyperventilation and cold air exercise.
    Rundell KW, Spiering BA, Baumann JM, Evans TM.
    Br J Sports Med; 2005 Apr 16; 39(4):232-6. PubMed ID: 15793094
    [Abstract] [Full Text] [Related]

  • 11. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast.
    Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF.
    Ann Allergy Asthma Immunol; 2006 Jul 16; 97(1):98-104. PubMed ID: 16892789
    [Abstract] [Full Text] [Related]

  • 12. Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction.
    Vidal C, Fernández-Ovide E, Piñeiro J, Nuñez R, González-Quintela A.
    Ann Allergy Asthma Immunol; 2001 Jun 16; 86(6):655-8. PubMed ID: 11428738
    [Abstract] [Full Text] [Related]

  • 13. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients.
    Lehnigk B, Rabe KF, Dent G, Herst RS, Carpentier PJ, Magnussen H.
    Eur Respir J; 1998 Mar 16; 11(3):617-23. PubMed ID: 9596112
    [Abstract] [Full Text] [Related]

  • 14. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group.
    Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, Gormley GJ, Pearlman DS.
    Ann Intern Med; 2000 Jan 18; 132(2):97-104. PubMed ID: 10644288
    [Abstract] [Full Text] [Related]

  • 15. Time-effect of montelukast on protection against exercise-induced bronchoconstriction.
    Peroni DG, Pescollderungg L, Sandri M, Chinellato I, Boner AL, Piacentini GL.
    Respir Med; 2011 Dec 18; 105(12):1790-7. PubMed ID: 21865022
    [Abstract] [Full Text] [Related]

  • 16. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children.
    Peroni DG, Piacentini GL, Pietrobelli A, Loiacono A, De Gasperi W, Sabbion A, Micciolo R, Boner AL.
    Eur Respir J; 2002 Jul 18; 20(1):104-7. PubMed ID: 12166555
    [Abstract] [Full Text] [Related]

  • 17. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
    Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A.
    Am J Respir Crit Care Med; 2002 Jan 01; 165(1):9-14. PubMed ID: 11779723
    [Abstract] [Full Text] [Related]

  • 18. Association of IL-13 polymorphisms with leukotriene receptor antagonist drug responsiveness in Korean children with exercise-induced bronchoconstriction.
    Kang MJ, Lee SY, Kim HB, Yu J, Kim BJ, Choi WA, Jang SO, Hong SJ.
    Pharmacogenet Genomics; 2008 Jul 01; 18(7):551-8. PubMed ID: 18551035
    [Abstract] [Full Text] [Related]

  • 19. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.
    Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP, Kundu S, Zhang J.
    J Allergy Clin Immunol; 1996 Sep 01; 98(3):528-34. PubMed ID: 8828530
    [Abstract] [Full Text] [Related]

  • 20. Urinary leukotriene E4 excretion in exercise-induced asthma.
    Taylor IK, Wellings R, Taylor GW, Fuller RW.
    J Appl Physiol (1985); 1992 Aug 01; 73(2):743-8. PubMed ID: 1328140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.